ADAR1 Capital Management, LLC has recently increased its stake in InMed Pharmaceuticals Inc., according to a filing with the SEC. This move is significant as it highlights ADAR1's growing confidence in the pharmaceutical industry, particularly in InMed's potential for growth.
Background
ADAR1 Capital Management, LLC is a Texas-based investment management firm. The company primarily focuses on managing private investment funds. Its recent filings indicate an active engagement in the market, particularly in the pharmaceutical sector, which is characterized by ongoing innovation and competition.
What the Filing Says
In the SEC filing dated October 8, 2026, ADAR1 reported several transactions involving common shares of InMed Pharmaceuticals. The filing details that on October 6, 2026, ADAR1 acquired 5,601 shares at a price of $1.3277 per share, followed by an additional 3,046 shares on October 7 at $1.33 each. Most recently, on October 8, the firm purchased 2,256 shares at a price of $1.3283. Following these transactions, ADAR1 now holds a total of 945,924 shares in InMed.
Impact
This increase in ownership may impact various stakeholders, including InMed Pharmaceuticals and its existing shareholders. ADAR1's significant stake could influence future corporate decisions, especially as the firm is now a ten percent owner. The filing indicates that these shares are owned directly by private investment funds managed by ADAR1, which also may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the firm's sole manager.
What's Next
The filing does not specify what happens next regarding ADAR1's investment strategy or any potential future transactions.